Matching articles for "Restasis"
Perfluorohexyloctane Ophthalmic Solution (Miebo) for Dry Eye Disease
The Medical Letter on Drugs and Therapeutics • January 22, 2024; (Issue 1694)
The FDA has approved perfluorohexyloctane
ophthalmic solution (Miebo – Bausch+Lomb) for
treatment of dry eye disease. Available only by
prescription, Miebo is the first ophthalmic product to be approved in...
The FDA has approved perfluorohexyloctane
ophthalmic solution (Miebo – Bausch+Lomb) for
treatment of dry eye disease. Available only by
prescription, Miebo is the first ophthalmic product to be approved in the US that specifically targets tear
evaporation caused by meibomian gland dysfunction.
An ophthalmic solution with a similar name, Meibo
Tears (Vista), which contains 0.6% propylene glycol, is
available over the counter for dry eye relief.
Varenicline Nasal Spray (Tyrvaya) for Dry Eye Disease
The Medical Letter on Drugs and Therapeutics • December 13, 2021; (Issue 1639)
Tyrvaya (Oyster Point), a nasal spray formulation
of the cholinergic agonist varenicline, has been
approved by the FDA for treatment of dry eye disease.
It is the first nasal spray to be approved in the...
Tyrvaya (Oyster Point), a nasal spray formulation
of the cholinergic agonist varenicline, has been
approved by the FDA for treatment of dry eye disease.
It is the first nasal spray to be approved in the US
for this indication. An oral formulation of varenicline
(Chantix, and generics) has been available for years
for smoking cessation.
Loteprednol 0.25% (Eysuvis) for Dry Eye Disease
The Medical Letter on Drugs and Therapeutics • May 17, 2021; (Issue 1624)
The FDA has approved loteprednol etabonate ophthalmic suspension 0.25% (Eysuvis – Kala) for
short-term treatment (≤2 weeks) of dry eye disease.
It is the first ocular corticosteroid to be approved...
The FDA has approved loteprednol etabonate ophthalmic suspension 0.25% (Eysuvis – Kala) for
short-term treatment (≤2 weeks) of dry eye disease.
It is the first ocular corticosteroid to be approved for
this indication. Other formulations of loteprednol are
approved for treatment of steroid-responsive ocular
inflammatory conditions, inflammation after ocular
surgery, and seasonal allergic conjunctivitis.
Drugs for Common Eye Disorders
The Medical Letter on Drugs and Therapeutics • December 2, 2019; (Issue 1586)
This issue includes reviews of drugs for glaucoma,
age-related macular degeneration (AMD), bacterial
conjunctivitis, and dry eye disease. Allergic conjunctivitis
is reviewed in a separate...
This issue includes reviews of drugs for glaucoma,
age-related macular degeneration (AMD), bacterial
conjunctivitis, and dry eye disease. Allergic conjunctivitis
is reviewed in a separate issue.
Cyclosporine 0.09% Solution (Cequa) for Dry Eye Disease
The Medical Letter on Drugs and Therapeutics • July 29, 2019; (Issue 1577)
The FDA has approved cyclosporine 0.09% ophthalmic
solution (Cequa – Sun) to increase tear production
in patients with keratoconjunctivitis sicca (dry eye
disease). Restasis, a 0.05% cyclosporine...
The FDA has approved cyclosporine 0.09% ophthalmic
solution (Cequa – Sun) to increase tear production
in patients with keratoconjunctivitis sicca (dry eye
disease). Restasis, a 0.05% cyclosporine emulsion,
was approved in the US in 2003 for the same indication.
Lifitegrast (Xiidra) for Dry Eye Disease
The Medical Letter on Drugs and Therapeutics • August 29, 2016; (Issue 1502)
The FDA has approved a 5% ophthalmic solution of
lifitegrast (Xiidra – Shire), a lymphocyte function-associated
antigen-1 (LFA-1) antagonist, for treatment
of the signs and symptoms of dry eye...
The FDA has approved a 5% ophthalmic solution of
lifitegrast (Xiidra – Shire), a lymphocyte function-associated
antigen-1 (LFA-1) antagonist, for treatment
of the signs and symptoms of dry eye disease.
Lifitegrast is the first LFA-1 antagonist to be approved
for any indication in the US.
Drugs for Some Common Eye Disorders
The Medical Letter on Drugs and Therapeutics • November 1, 2012; (Issue 123)
Drugs for glaucoma, age-related macular degeneration,
bacterial conjunctivitis, and dry eyes are
reviewed here. Drugs for the treatment of allergic conjunctivitis
will be reviewed in a future issue...
Drugs for glaucoma, age-related macular degeneration,
bacterial conjunctivitis, and dry eyes are
reviewed here. Drugs for the treatment of allergic conjunctivitis
will be reviewed in a future issue of
Treatment Guidelines on Drugs for Allergic Disorders.
Drugs for Some Common Eye Disorders
The Medical Letter on Drugs and Therapeutics • January 1, 2010; (Issue 89)
Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly...
Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly patients, the complexity of self-administering numerous ophthalmic drugs may be the limiting factor in their ability to care for themselves. Drugs for the treatment of allergic conjunctivitis will be reviewed in a future issue of Treatment Guidelines on Drugs for Allergic Disorders.
Drugs for Some Common Eye Disorders
The Medical Letter on Drugs and Therapeutics • January 1, 2007; (Issue 53)
Drugs for glaucoma, age-related macular degeneration, bacterial and allergic conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some...
Drugs for glaucoma, age-related macular degeneration, bacterial and allergic conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly patients, the complexity of self-administering numerous ophthalmic drugs may be the limiting factor in their ability to care for themselves.
Ophthalmic Cyclosporine (Restasis) for Dry Eyes
The Medical Letter on Drugs and Therapeutics • May 26, 2003; (Issue 1157)
A cyclosporine 0.05% ophthalmic emulsion (Restasis - Allergan) has been approved by the FDA for use in patients with dry eye disease (keratoconjunctivitis sicca). This review begins with a discussion of the...
A cyclosporine 0.05% ophthalmic emulsion (Restasis - Allergan) has been approved by the FDA for use in patients with dry eye disease (keratoconjunctivitis sicca). This review begins with a discussion of the causes of dry eye disease and includes sections on the pharmacology, adverse effects and clinical trial results for ophthalmic cyclosporine. Cost information and recommendations for administering the drug are also presented. The review concludes with an overall assessment of the drug's efficacy, safety and cost.